Article Text

PDF
THU0651 Should we reduce the dose of biological therapy to all patients with inflammatory arthritis achieving sustained therapeutic goal?
  1. I Gonzalez-Alvaro1,
  2. C Sánchez-Piedra2,
  3. R Almodovar3,
  4. J Bachiller4,
  5. A Balsa5,
  6. AJ Blasco6,
  7. R Caliz7,
  8. G Candelas8,
  9. C Fernández-Carballido9,
  10. A García-Aparicio10,
  11. B García-Magallόn11,
  12. R García-Vicuña1,
  13. A Gomez-Centeno12,
  14. AM Ortiz1,
  15. R Sanmartí13,
  16. J Sanz14,
  17. B Tejera15,
  18. I Notario7,
  19. MJ Soto7,
  20. C Plasencia5,
  21. V Hernández15,
  22. M Espinosa14,
  23. C Ramos14,
  24. P Lazaro6
  1. 1Rheumatology, HU la Princesa
  2. 2Research Unit, SER, Madrid
  3. 3Rheumatology, HU Fundaciόn Alcorcόn, Alcorcόn
  4. 4Rheumatology, HU Ramon y Cajal
  5. 5Rheumatology, HU la Paz
  6. 6Independent Health Services Researcher, Madrid
  7. 7Rheumatology, HU Virgen de la Nieves, Granada
  8. 8Rheumatology, Hospital Clínico San Carlos, Madrid
  9. 9Rheumatology, Hospital General Universitario, Elda
  10. 10Rheumatology, Hospital Virgen de la Salud, Toledo
  11. 11Rheumatology, Hospital Gral San Jorge, Huesca
  12. 12Rheumatology, HU Parc Taulí, Sabadell
  13. 13Rheumatology, Hospital Clinic, Barcelona
  14. 14Rheumatology, HU Puerta de Hierro, Majadahonda
  15. 15Rheumatology, HU Canarias, Sta Cruz Tenerife, Spain

Abstract

Background Dose tapering of biological therapies (BT) in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) is frequent in Spain. However, there is variability in BT optimization (BTO). So, Spanish Society of Rheumatology published in 2015 recommendations on how to optimize BT (1). Nevertheless, there is no solid evidence on which patient profiles BTO is appropriated.

Objectives To develop appropriateness criteria for BTO in patients with RA, axial SpA (axSpA) or peripheral SpA (pSpA)

Methods The RAND/UCLA appropriateness method was used. Five rheumatologists experienced in RA and/or SpA clinical research selected and defined the variables considered relevant when deciding reduction of BT in order to define patient profiles. Ten BT experienced rheumatologists anonymously rated 1 (completely inappropriate) to 9 (completely appropriate) each profile after reading evidence synthesis. Then, in a meeting, classification variables and profiles with disagreement were revised and all profiles were scored again. Profiles with a median score >6 were considered appropriate, those with a median score <3.5 were considered inappropriate and the remaining uncertain. In addition, a study of the prevalence of these profiles was performed in 9 Spanish hospitals.

Results Combining the options of variables 2,304 different profiles were obtained for RA, 768 for axSpA, and 3,072 for pSpA. 327 (14.2%) profiles in RA, 80 (10.4%) in axSpA, and 154 (5%) in pSpA were considered appropriate for BT dose reduction. By contrast, 749 (53.3%) profiles in RA, 270 (54.4%) in axSpA, and 1243 (54.5%) in pSpA were considered inappropriate. The remaining profiles were considered uncertain. In the preliminary study to determine profiles prevalence, we collected information from 242 RA, 171 axSpA and 172 pSpA patients that underwent BTO. We found that BTO was performed appropriately in 23% RA, 67% axSpA and 61% pSpA patients. BTO was indicated in uncertain profiles in 67% RA, 23% axSpA and 37% pSpA patients. Only in RA we detected BT dose reduction in patient profiles considered inappropriate (2%).

Conclusions Appropriateness criteria for BT dose reduction in three inflammatory conditions were developed and the preliminary prevalence study suggests that BTO was wiselly applied. However, further research in this field is needed to determine the real prevalence of clinical profiles of patients undergoing BTO in daily clinical practice and validate these criteria in real life.

References

  1. Gonzalez-Alvaro I et al. Rheumatology 2015; 54: 1200–1209.

References

Disclosure of Interest I. Gonzalez-Alvaro: None declared, C. Sánchez-Piedra Grant/research support from: Unrestricted grant from Abbvie, R. Almodovar: None declared, J. Bachiller: None declared, A. Balsa: None declared, A. Blasco Grant/research support from: Unrestricted grant from Abbvie, R. Caliz: None declared, G. Candelas: None declared, C. Fernández-Carballido: None declared, A. García-Aparicio: None declared, B. García-Magallόn: None declared, R. García-Vicuña: None declared, A. Gomez-Centeno: None declared, A. Ortiz: None declared, R. Sanmartí: None declared, J. Sanz: None declared, B. Tejera: None declared, I. Notario: None declared, M. Soto: None declared, C. Plasencia: None declared, V. Hernández: None declared, M. Espinosa: None declared, C. Ramos: None declared, P. Lazaro Grant/research support from: Unrestricted grant from Abbvie

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.